Search results for "Autoimmune hepatiti"

showing 10 items of 106 documents

Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter.

2017

Background & Aims Controlled attenuation parameter (CAP) can be performed together with liver stiffness measurement (LSM) by transient elastography (TE) and is often used to diagnose fatty liver. We aimed to define the validity criteria of CAP. Methods CAP was measured by the M probe prior to liver biopsy in 754 consecutive patients with different liver diseases at three centers in Europe and Hong Kong (derivation cohort, n = 340; validation cohort, n = 414; 101 chronic hepatitis B, 154 chronic hepatitis C, 349 non-alcoholic fatty liver disease, 37 autoimmune hepatitis, 49 cholestatic liver disease, 64 others; 277 F3-4; age 52 ± 14; body mass index 27.2 ± 5.3 kg/m2). The primary outco…

AdultMalemedicine.medical_specialtyBiopsyAutoimmune hepatitisHepatic steatosiDiagnostic accuracyGastroenterology03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicineNonalcoholic fatty liver diseaseMedicineHumansLiver stiffness measurementAgedFibroScanHepatologymedicine.diagnostic_testbusiness.industryFatty liverReproducibility of ResultsLiver biopsyHepatologyMiddle Agedmedicine.diseaseFatty LiverCross-Sectional StudiesLiverROC Curve030220 oncology & carcinogenesisLiver biopsyElasticity Imaging Techniques030211 gastroenterology & hepatologyFemaleSteatosisTransient elastographybusinessNon-alcoholic fatty liver diseaseJournal of hepatology
researchProduct

Long-term outcome after living donor liver transplantation compared to donation after brain death in autoimmune liver diseases: Experience from the E…

2021

Knowledge of living donor liver transplantation (LDLT) for autoimmune liver diseases (AILDs) is scarce. This study analyzed survival in LDLT recipients registered in the European Liver Transplant Registry with autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis (PSC) and the non-autoimmune disorder alcohol-related cirrhosis. In total, 29 902 individuals enrolled between 1998 and 2017 were analyzed, including 1003 with LDLT. Survival from >90 days after LDLT for AILDs in adults was 85.5%, 74.2%, and 58.0% after 5, 10, and 15 years. Adjusted for recipient age, sex, and liver transplantation era, adult PSC patients receiving LDLT showed increased mortality compare…

AdultMalemedicine.medical_specialtyBrain DeathCirrhosisMultivariate analysis[SDV]Life Sciences [q-bio]Medizinliving donorDiseaseAutoimmune hepatitisinflammatory030230 surgeryclinical research/practiceGastroenterologyPrimary sclerosing cholangitis03 medical and health sciences0302 clinical medicinepatient survivalInternal medicinemedicinePrimary Sclerosing CholangitisLiving DonorsImmunology and AllergyRisk-FactorsHumansPharmacology (medical)RegistriesChildRetrospective StudiesTransplantationbusiness.industryLiver DiseasesHazard ratioGraft SurvivalCohort[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologymedicine.disease3. Good healthDonation after brain deathLiver TransplantationTreatment Outcome030211 gastroenterology & hepatologyimmuneMorbidityLiving donor liver transplantationbusinessliver diseaseliver transplantation/hepatologyAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant SurgeonsREFERENCES
researchProduct

Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: a retrospective cohort study.

2014

Abstract Background Drugs and herbal products can induce autoimmune hepatitis. We assessed frequency and clinical outcomes of patients suffering from drug-induced autoimmune hepatitis. Methods All patients with drug-induced liver injury admitted between 2000 and 2011 were retrospectively studied. Diagnoses of drug-induced autoimmune hepatitis and idiopathic autoimmune hepatitis were made according to simplified criteria. After discharge, all patients had regular follow-up and were contacted to update outcomes. Results Among 10,270 in-hospital patients, 136 (1.3%) were diagnosed with drug-induced liver injury. Among them, 12 (8.8%) were diagnosed as drug-induced autoimmune hepatitis (41.7% m…

AdultMalemedicine.medical_specialtyDrug-induced liver injuryAdolescentAutoimmunityAutoimmune hepatitisSettore MED/08 - Anatomia Patologicamedicine.disease_causeGastroenterologyAutoimmunityYoung AdultInternal medicinemedicineHumansAutoimmunity; Drug-induced liver injury; Human leucocyte antigens; Liver biopsy --------------------------------------------------------------------------------Liver biopsy --------------------------------------------------------------------------------AgedRetrospective StudiesSettore MED/04 - Patologia GeneraleLiver injurySettore MED/12 - GastroenterologiaHepatologymedicine.diagnostic_testbusiness.industryGastroenterologyGamma globulinRetrospective cohort studyHuman leucocyte antigenJaundiceMiddle Agedmedicine.diseaseHepatitis AutoimmuneTreatment OutcomeLiver biopsyCohortImmunologyFemalemedicine.symptomChemical and Drug Induced Liver InjurybusinessImmunosuppressive AgentsFollow-Up StudiesDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

The aetiology of chronic hepatitis in Italy: results from a multicentre national study

2004

Background: No recent national-level data on the aetiology of chronic hepatitis are available in Italy. Aim: To evaluate the current aetiology of chronic hepatitis in Italy. Patients: A total of 6210 chronic hepatitis patients (both prevalence and incident cases) consecutively admitted to 79 hospitals located throughout Italy were enrolled over a 6-month period in 2001. The hospitals were randomly selected through systematic cluster sampling. Results: The main agent associated with chronic hepatitis was hepatitis C virus, which was found in 76.5% of the patients (in 62.6% it was the only aetiologic factor). Hepatitis B surface antigen was present in the serum of 12.2% of the cases (in 9.2% …

AdultMalemedicine.medical_specialtyHBsAgHepatitis D ChronicEpidemiologyHepatitis C virusAutoimmune hepatitismedicine.disease_causeAutoimmune DiseasesHepatitis B ChronicInternal medicinemedicinePrevalenceHumansHepatitis B virusHepatologybusiness.industryGastroenterologyHepatitis CHepatitis BHepatitis C ChronicMiddle Agedmedicine.diseaseHepatitis DHBeAgItalyImmunologyChronic hepatitiFemalechronic hepatitis; epidemiology; italychronic hepatitisbusiness
researchProduct

Post-infantile giant cell hepatitis in patients with primary sclerosing cholangitis and autoimmune hepatitis.

2008

In post-infancy, multinucleated giant cell hepatitis is rare. Various conditions and diseases associated with post-infantile giant cell hepatitis have been described, but the pathogenesis remains unknown. In this paper we review the case reports of four patients (3 male, 1 female; aged 22 to 32 years) with primary sclerosing cholangitis and autoimmune hepatitis. The follow-up ranges from five to seven years. All patients showed cholestasis and repeated elevation of hepatic transaminases. Patients with viral infections, metabolic disorders and toxic influences were excluded. Histopathology of liver tissue in all four patients revealed giant cell formation with up to 20 nuclei in 20-70% of al…

AdultMalemedicine.medical_specialtyPathologyCirrhosisCholangitisAutoimmunityAutoimmune hepatitisGiant CellsPrimary sclerosing cholangitisHepatitisCholestasisAdrenal Cortex HormonesHLA AntigensmedicineHumansAspartate AminotransferasesAutoimmune diseaseHepatitisCholangiopancreatography Endoscopic RetrogradeCholestasisHepatologybusiness.industryHistocytochemistryUrsodeoxycholic AcidAlanine TransaminaseBilirubinmedicine.diseaseSerologyGiant cellHistopathologyFemalebusinessImmunosuppressive AgentsLiver
researchProduct

Anti-actin antibodies in celiac disease: correlation with intestinal mucosa damage and comparison of ELISA with the immunofluorescence assay.

2005

The presence in the sera of celiac disease (CD) patients of anti-actin autoantibodies (AAAs) has been suggested as a marker of severe intestinal villus atrophy (1). AAAs have been detected with an immunofluorescence (IF) technique and seem to contribute to villus cytoskeleton damage and to the pathogenesis of intestinal damage in CD (2). The aims of the present study were to evaluate the relationship between the presence of serum IgA AAAs and severity of intestinal mucosa damage in CD patients and to compare the IF assay with a new ELISA for IgA AAA determination. We enrolled 150 individuals in the study. IgA AAAs were assayed in 58 consecutive CD patients diagnosed between January and Dece…

AdultMalemedicine.medical_specialtyPathologySettore MED/09 - Medicina InternaAdolescentClinical Biochemistryanti-actin autoantibodieFluorescent Antibody TechniqueEnzyme-Linked Immunosorbent AssayAutoimmune hepatitisGastroenterologyCoeliac diseasePrimary biliary cirrhosisIntestinal mucosaInternal medicinemedicineHumansIntestinal MucosaChildPediatric gastroenterologyAutoantibodiesbusiness.industryBiochemistry (medical)Intestinal villusAutoantibodyInfantMiddle Agedmedicine.diseaseActinsImmunoglobulin AFood intoleranceanti-actin autoantibodies; celiac disease; ELISAmedicine.anatomical_structureChild PreschoolFemaleELISAbusinessceliac disease
researchProduct

Posttransfusional, LKM-1-autoantibody-positive hepatitis C virus infection, cryoglobulinemia, and aplastic anemia.

1995

Aplastic anemia is occasionally caused by viral hepatitis, hepatitis C virus being the most important factor. Pathogenetically, decreased bone marrow function, abnormalities of the bone marrow microenvironment, and immune-mediated suppression of hematopoiesis are important. Hepatitis C virus infection is associated with a variety of extrahepatic manifestations including autoimmune features like cryoglobulinemia, Sjogren's syndrome, and autoimmune hepatitis. Here we report the case of a 42-year-old man with aplastic anemia due to posttransfusional hepatitis C virus infection associated with cryoglobulinemia and LKM-1 autoantibodies. Following a triple immunosuppressive therapy, there was a c…

AdultMalemedicine.medical_specialtyPhysiologyHepatitis C virusAutoimmune hepatitismedicine.disease_causeBone MarrowInternal medicinemedicineHumansAplastic anemiaAutoantibodiesbusiness.industryGastroenterologyAutoantibodyAnemia AplasticTransfusion ReactionHepatologymedicine.diseaseVirologyCryoglobulinemiaHepatitis Cmedicine.anatomical_structureCryoglobulinemiaImmunologyBone marrowbusinessViral hepatitisDigestive diseases and sciences
researchProduct

Duration of immunosuppressive therapy in autoimmune hepatitis

2001

AdultMalemedicine.medical_specialtyTime FactorsAdolescentmedicine.drug_classmedicine.medical_treatmentMEDLINEAutoimmune hepatitisGastroenterologyRemission inductionRecurrenceInternal medicinemedicineHumansChildAgedAutoimmune diseaseHepatitisChemotherapyHepatologybusiness.industryRemission InductionMiddle Agedmedicine.diseaseHepatitis AutoimmuneImmunologyCorticosteroidFemalebusinessImmunosuppressive AgentsJournal of Hepatology
researchProduct

Analysis of the in vitro cytokine production by liver-infiltrating T cells of patients with autoimmune hepatitis.

1993

SUMMARY The pathogenic mechanisms underlying the development of autoimmune hepatitis (AIH) are still unclear. Since AIH is associated with the presence of various autoantibodics and certain HLA subtypes, it is likely that T and B cells play a major role in this disease. In this study we have determined the functional capacities of in vivo preactivated liver-infiltrating T cells (LTC) from patients with AIH. As controls we used LTC from patients with non-autoimmune hepatitis (non-AIH). Our results show that preactivated LTC from patients with AIH predominantly (190/255 clones) reside in the CD4+ population, whereas LTC in non-AIH are dominated by the CD8+ phenotype (148/254 clones). In view …

AdultMalemedicine.medical_treatmentT cellCD8 AntigensT-LymphocytesImmunologyPopulationAutoimmune hepatitisHuman leukocyte antigenBiologyAutoimmune DiseasesHepatitisInterferon-gammaImmune systemimmune system diseasesmedicineImmunology and AllergyHumanseducationeducation.field_of_studyTumor Necrosis Factor-alphaInterleukinsMiddle Agedmedicine.diseasedigestive system diseasesClone CellsCytokinemedicine.anatomical_structureLiverImmunologyCD4 AntigensCytokinesCytokine secretionFemaleCD8Research ArticleClinical and experimental immunology
researchProduct

Identification of cyclin A as a molecular target of antinuclear antibodies (ANA) in hepatic and non-hepatic autoimmune diseases.

1996

Abstract Background/Aims: Antinuclear antibodies (ANA) are a diagnostic of various autoimmune diseases and also of autoimmune hepatitis type 1. The designation ANA describes a heterogeneous group of autoantibodies. In liver diseases, only a few nuclear target antigens have been molecularly identified and characterized. Cyclins play a central role in a cell cycle regulation, DNA transcription, and cell proliferation. Cyclin A was also identified as an integration site of the hepatitis B virus in a patient with hepatocellular carcinoma. In this study we identify cyclin A as a novel nuclear target protein of ANA. Methods: Sera of patients with autoimmune hepatitis (AIH) type 1 ( n =61), type 2…

AdultPathologymedicine.medical_specialtyAnti-nuclear antibodyCyclin ABlotting WesternImmunoblottingEnzyme-Linked Immunosorbent AssayAutoimmune hepatitisImmunofluorescenceAutoantigensAutoimmune DiseasesMixed connective tissue diseaseimmune system diseasesCyclinsMedicineHumansLupus Erythematosus Systemicskin and connective tissue diseasesFluorescent Antibody Technique IndirectAutoantibodiesAutoimmune diseaseHepatologymedicine.diagnostic_testbiologybusiness.industryLiver DiseasesAutoantibodyDNAMiddle Agedmedicine.diseaseRecombinant ProteinsAntibodies AntinuclearImmunologybiology.proteinAntibodybusinessBaculoviridaeJournal of hepatology
researchProduct